NASDAQ: MLTX
Moonlake Immunotherapeutics Stock Ownership - Who owns Moonlake Immunotherapeutics?

Insider buying vs selling

Have Moonlake Immunotherapeutics insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Catherine MoukheibirDirector2025-07-0323,500$48.79
$1.15MSell
Bvf Partners L PDirector2024-10-04132,549$50.00
$6.63MSell
Bvf Partners L PDirector2024-10-04836,862$50.00
$41.84MSell
Bvf Partners L PDirector2024-10-041,030,589$50.00
$51.53MSell
Simon SturgeDirector2024-10-04171,000$53.72
$9.19MSell

1 of 1

MLTX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when MLTX insiders and whales buy or sell their stock.

MLTX Shareholders

What type of owners hold Moonlake Immunotherapeutics stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Bvf Inc30.76%19,751,284$996.65MInstitution
Bihua Chen17.67%11,344,151$572.43MInsider
Cormorant Asset Management LP13.23%8,494,151$428.61MInstitution
Fmr LLC9.85%6,327,014$319.26MInstitution
Helix Holdings LLC5.01%3,215,000$162.23MInsider
Da Silva Jorge Santos4.80%3,078,577$155.34MInsider
Kristian Reich4.69%3,009,940$151.88MInsider
Price T Rowe Associates Inc4.63%2,973,830$150.06MInstitution
Avoro Capital Advisors LLC4.31%2,770,100$139.78MInstitution
Citadel Advisors LLC2.30%1,478,635$74.61MInstitution

1 of 3

MLTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
MLTX72.50%27.50%Net SellingNet Selling
AAPG0.07%0.00%
PTGX81.75%18.25%Net SellingNet Selling
MTSR43.57%56.43%Net Buying
SRRK59.83%40.17%Net SellingNet Selling

Moonlake Immunotherapeutics Stock Ownership FAQ

Who owns Moonlake Immunotherapeutics?

Moonlake Immunotherapeutics (NASDAQ: MLTX) is owned by 93.29% institutional shareholders, 35.39% Moonlake Immunotherapeutics insiders, and 0.00% retail investors. Bihua Chen is the largest individual Moonlake Immunotherapeutics shareholder, owning 11.34M shares representing 17.67% of the company. Bihua Chen's Moonlake Immunotherapeutics shares are currently valued at $572.20M.

If you're new to stock investing, here's how to buy Moonlake Immunotherapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.